Gross Profit Margin (Quarterly) Chart

View Gross Profit Margin (Quarterly) for SWDCF.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Gross Profit Margin (Quarterly) Chart
Start Trial

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 2015. Start Trial.
Date Value
June 30, 2026 7.63%
March 31, 2026 7.60%
December 31, 2025 3.84%
September 30, 2025 6.78%
June 30, 2025 3.54%
March 31, 2025 6.72%
December 31, 2024 8.35%
September 30, 2024 8.41%
June 30, 2024 9.42%
March 31, 2024 8.92%
December 31, 2023 8.77%
September 30, 2023 7.94%
June 30, 2023 5.31%
March 31, 2023 6.06%
December 31, 2022 6.80%
September 30, 2022 3.54%
June 30, 2022 7.05%
March 31, 2022 8.92%
December 31, 2021 6.35%
September 30, 2021 9.61%
June 30, 2021 13.64%
March 31, 2021 8.91%
December 31, 2020 12.73%
Date Value
September 30, 2020 30.22%
June 30, 2020 20.30%
March 31, 2020 25.08%
December 31, 2019 21.45%
September 30, 2019 33.98%
June 30, 2019 27.47%
March 31, 2019 33.06%
December 31, 2018 26.28%
September 30, 2018 35.75%
June 30, 2018 26.42%
March 31, 2018 26.15%
December 31, 2017 27.22%
September 30, 2017 27.90%
June 30, 2017 17.32%
March 31, 2017 31.05%
December 31, 2016 3.78%
September 30, 2016 31.43%
June 30, 2016 20.40%
March 31, 2016 29.98%
December 31, 2015 -7.68%
September 30, 2015 40.56%
June 30, 2015 41.97%
March 31, 2015 37.35%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
Orexo AB -137.1%
Camurus AB 92.70%
Moberg Pharma AB 65.36%
Infant Bacterial Therapeutics AB --
AstraZeneca PLC 76.09%